Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
McCune TR et al. | Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. | 1998 | Transplantation | pmid:9448150 |
Mentzer RM et al. | Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The U.S. Multicenter FK506 Study Group. | 1998 | Transplantation | pmid:9448154 |
Burroughs TE et al. | Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. | 2007 | Transplantation | pmid:17452891 |
First MR | Transplantation in the nineties. | 1992 | Transplantation | pmid:1370734 |
Eason JD et al. | Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. | 2003 | Transplantation | pmid:12717237 |
Neylan JF | Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. | 1998 | Transplantation | pmid:9500626 |
Misra S et al. | Red cell aplasia in children on tacrolimus after liver transplantation. | 1998 | Transplantation | pmid:9500636 |
Hougardy JM et al. | The once-daily formulation of tacrolimus: a step forward in kidney transplantation? | 2012 | Transplantation | pmid:22234346 |
Yasunami Y et al. | FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. | 1990 | Transplantation | pmid:1691535 |
Kim YI et al. | Stimulation of liver regeneration by pretreatment with azathioprine as well as cyclosporine and FK506. | 1992 | Transplantation | pmid:1373539 |
Metcalfe SM and Richards FM | Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. | 1990 | Transplantation | pmid:1691537 |
D'Antiga L et al. | Late cellular rejection in paediatric liver transplantation: aetiology and outcome. | 2002 | Transplantation | pmid:11792983 |
Butani L et al. | Effect of felodipine on tacrolimus pharmacokinetics in a renal transplant recipient. | 2002 | Transplantation | pmid:11793001 |
Ferraris JR et al. | Conversion from cyclosporine A to tacrolimus in pediatric kidney transplant recipients with chronic rejection: changes in the immune responses. | 2004 | Transplantation | pmid:15084930 |
Shapiro R et al. | Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. | 1999 | Transplantation | pmid:10628763 |
Velidedeoglu E et al. | Early kidney dysfunction post liver transplantation predicts late chronic kidney disease. | 2004 | Transplantation | pmid:15084934 |
Leung W et al. | Long-term complete remission and immune tolerance after intensive chemotherapy for lymphoproliferative disorders complicating liver transplant. | 1999 | Transplantation | pmid:10385092 |
Andrés A et al. | A randomized trial comparing renal function in older kidney transplant patients following delayed versus immediate tacrolimus administration. | 2009 | Transplantation | pmid:19898206 |
Kessler M et al. | A renal allograft recipient with late recurrence of focal and segmental glomerulosclerosis after switching from cyclosporine to tacrolimus. | 1999 | Transplantation | pmid:10071045 |
Xu X et al. | FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506. | 2002 | Transplantation | pmid:12085010 |
Mueller AR et al. | Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506. | 1994 | Transplantation | pmid:7518974 |
Takaya S et al. | Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1. | 1992 | Transplantation | pmid:1279851 |
Wasik M et al. | Effect of FK506 versus cyclosporine on human natural and antibody-dependent cytotoxicity reactions in vitro. | 1991 | Transplantation | pmid:1702910 |
Carroll PB et al. | Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans. | 1991 | Transplantation | pmid:1702911 |
Saliba F et al. | Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study. | 2016 | Transplantation | pmid:27454919 |
Sarwal MM et al. | Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. | 2001 | Transplantation | pmid:11468528 |
Nobori S et al. | Long-term acceptance of fully allogeneic cardiac grafts by cotransplantation of vascularized thymus in miniature swine. | 2006 | Transplantation | pmid:16421473 |
Tokita D et al. | High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance. | 2008 | Transplantation | pmid:18301333 |
Luan FL et al. | New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. | 2011 | Transplantation | pmid:21242885 |
Yoshimura N et al. | Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2. | 1989 | Transplantation | pmid:2465593 |
Takatsuki M et al. | Weaning of immunosuppression in living donor liver transplant recipients. | 2001 | Transplantation | pmid:11502975 |
Shapiro R et al. | Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. | 2008 | Transplantation | pmid:18431232 |
Meier M et al. | Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: a randomized controlled trial. | 2006 | Transplantation | pmid:16612281 |
Iwata H et al. | Suppression of allograft responses by combining donor alloantigen-specific intravenous presensitization with suboptimal doses of FK506. | 1993 | Transplantation | pmid:7687396 |
Stempfle HU et al. | The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. | 2002 | Transplantation | pmid:11889427 |
Panz VR et al. | Diabetogenic effect of tacrolimus in South African patients undergoing kidney transplantation1. | 2002 | Transplantation | pmid:11889436 |
Charney DA et al. | Plasma cell-rich acute renal allograft rejection. | 1999 | Transplantation | pmid:10515379 |
Brunet M et al. | Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. | 2006 | Transplantation | pmid:16495801 |
Chen H et al. | Compromised kidney graft rejection response in Vervet monkeys after withdrawal of immunosuppressants tacrolimus and sirolimus. | 2000 | Transplantation | pmid:10836361 |
Randhawa PS et al. | Clinical significance of renal biopsies showing concurrent acute rejection and tacrolimus-associated tubular vacuolization. | 1999 | Transplantation | pmid:9921801 |
Hougardy JM et al. | Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. | 2011 | Transplantation | pmid:21192316 |
Stevens C et al. | The effects of immunosuppressive agents on in vitro production of human immunoglobulins. | 1991 | Transplantation | pmid:1710843 |
Bayés B et al. | Adiponectin and risk of new-onset diabetes mellitus after kidney transplantation. | 2004 | Transplantation | pmid:15257035 |
Miao G et al. | Development of donor-specific immunoregulatory T-cells after local CTLA4Ig gene transfer to pancreatic allograft. | 2004 | Transplantation | pmid:15257039 |
Wang X et al. | Immunosuppression with a combination of pg490-88 and a subtherapeutic dose of FK506 in a canine renal allograft model. | 2005 | Transplantation | pmid:15940043 |
Bendahan J et al. | The effect of administration of FK506 on delayed regeneration in flushed partially hepatectomized livers. | 1994 | Transplantation | pmid:7511255 |
Chavin KD et al. | Anti-CD2 monoclonal antibodies synergize with FK506 but not with cyclosporine or rapamycin to induce tolerance. | 1994 | Transplantation | pmid:7511258 |
Ricordi C et al. | In vivo effect of FK506 on human pancreatic islets. | 1991 | Transplantation | pmid:1716797 |
Wiesner RH | A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. | 1998 | Transplantation | pmid:9734494 |
Chan L et al. | Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. | 2010 | Transplantation | pmid:20517177 |